These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 34526854)

  • 21. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.
    Lee SJ; Cha JJ; Choi WG; Lee WS; Jeong JO; Choi S; Cho YH; Park W; Yoon CH; Lee YJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Hong SJ; Kim JS;
    JAMA Cardiol; 2023 Sep; 8(9):853-858. PubMed ID: 37531130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis.
    Dolezelova E; Stein E; Derosa G; Maffioli P; Nachtigal P; Sahebkar A
    Br J Clin Pharmacol; 2017 Jul; 83(7):1380-1396. PubMed ID: 28166606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
    Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
    Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
    Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L
    Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers.
    Wu NQ; Guo YL; Zhu CG; Gao Y; Zhao X; Sun D; Sun J; Xu RX; Liu G; Dong Q; Li JJ
    Lipids Health Dis; 2018 Nov; 17(1):265. PubMed ID: 30470229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A; Simental-Mendía LE; Pirro M; Banach M; Watts GF; Sirtori C; Al-Rasadi K; Atkin SL
    Sci Rep; 2018 Dec; 8(1):17887. PubMed ID: 30552391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
    Toth PP; Ballantyne CM; Davidson MH; Tomassini JE; Ramey DR; Neff D; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2012; 6(2):180-91. PubMed ID: 22385552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial.
    Lv X; Liu X; Peng Y; Li W; Wang J; Chen X; Lei J; Tang C; Luo S; Mai W; Cai Y; Fan Q; Liu C; Zhang L
    J Stroke Cerebrovasc Dis; 2024 May; 33(5):107647. PubMed ID: 38431112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis.
    Mikhailidis DP; Lawson RW; McCormick AL; Sibbring GC; Tershakovec AM; Davies GM; Tunceli K
    Curr Med Res Opin; 2011 Jun; 27(6):1191-210. PubMed ID: 21473671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes.
    Park SY; Jun JE; Jeong IK; Ahn KJ; Chung HY; Hwang YC
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1883-1890. PubMed ID: 38175670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
    Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
    Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.
    Thompson PD; MacDougall DE; Newton RS; Margulies JR; Hanselman JC; Orloff DG; McKenney JM; Ballantyne CM
    J Clin Lipidol; 2016; 10(3):556-67. PubMed ID: 27206943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.